Table 2.

Clinical characteristics of patients who underwent blood purification therapy

Characteristics	All n = 28	SARS-CoV-2 positive n = 7	SARS-CoV-2 negative n = 11	RT-PCR not performed n = 10
Age (years)	77 [63–81]	81 [59–83]	78 [70–79]	67 [60–79]
Sex, male n (%)	22 (79)	5 (71)	9 (82)	8 (80)
Body mass index (kg/m2)	21 [19–25]	20 [19–22]	20 [19–21]	24 [22–28]
Purpose of admission n (%)
Initiation of HD	9 (32)	3 (43)	2 (18)	4 (40)
Treatment for complicated disease	14 (50)	1 (14)	8 (73)	5 (50)
Therapy for AKI	4 (14)	3 (43)	1 (9)	0 (0)
Others	1 (4)	0 (0)	0 (0)	1 (10)
Dialysis vintage (months)	7 [0–53]	0 [0–1]	17 [1–97]	11 [0–60]
Dialysis sessions (counts)	7 [3–9]	7 [3–9]	9 [8–12]	3 [2–4]
AKI n (%)	4 (14)	3 (43)	1 (9)	0 (0)
Hypertension n (%)	24 (86)	7 (100)	10 (91)	7 (70)
Diabetes mellitus n (%)	15 (54)	6 (86)	4 (36)	5 (50)
Coronary artery disease n (%)	8 (29)	2 (29)	5 (45)	1 (10)
Malignancy current n (%)	6 (21)	1 (14)	2 (18)	3 (30)
Smoking history n (%)	24 (86)	7 (100)	10 (91)	7 (70)
ACEi or ARB use n (%)	8 (29)	2 (29)	3 (27)	3 (30)
Dialysis access n (%)
Dialysis catheter use	8 (29)	4 (57)	3 (27)	1 (10)
ADL status
Charlson comorbidity index	6 [2–8]	6 [5–8]	5 [2–9]	5 [2–7]
Charlson comorbidity index ≥ 5, n (%)	22 (79)	7 (100)	6 (55)	9 (90)
Dementia severe n (%)	6 (21)	3 (43)	2 (18)	1 (10)
Level of dependency (medium and high) n (%)	12 (43)	6 (86)	4 (36)	2 (20)
Level of dependency (high) n (%)	6 (21)	4 (5)	1 (9)	1 (10)
Ward with nosocomial infection n (%)	16 (57)	7 (100)	5 (45)	4(40)
Admission to a private room n (%)	5 (18)	3 (43)	2 (18)	0 (0)

Data are presented as n (%) or median [interquartile range]

SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, RT-PCR reverse transcription polymerase chain reaction, HD hemodialysis, AKI acute kidney injury, ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blocker, ADL activity of daily living